Form 4: Zai Lab Legal Officer Sells 14,328 ADSs

Zai Lab's Chief Legal Officer, Frazor Titus III Edmondson, reported the sale of 14,328 American Depositary Shares at $19.78 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Frazor Titus III Edmondson, Chief Legal Officer of Zai Lab Ltd., reported a sale of company securities.
• The transaction involved the disposition of 14,328 American Depositary Shares (ADSs).
• The sale occurred on November 21, 2025, at a price of $19.78 per ADS.
• Following this transaction, Edmondson beneficially owns 27,737 ADSs.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024.
• Each American Depositary Share (ADS) represents ten Ordinary Shares of Zai Lab Ltd.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale, it was conducted under a Rule 10b5-1 plan, which typically indicates a pre-scheduled personal financial management event rather than a reaction to new company-specific information. Therefore, it carries less negative signaling than an unplanned insider sale.

Future Outlook

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled sale rather than a discretionary one based on immediate market conditions.

Industry Context

This is a routine insider transaction disclosure for a publicly traded biotechnology company, common across all industries for executives managing personal portfolios.

Stakeholder Impact

• Shareholders may note the reduction in the Chief Legal Officer's direct holdings, though the Rule 10b5-1 plan mitigates concerns about the timing of the sale.

Key Dates

Keywords

Zai Lab, ZLAB, Form 4, Insider Trading, Stock Sale, American Depositary Shares, ADS, Rule 10b5-1, Chief Legal Officer, Edmondson Frazor Titus III